[CAS NO. 1029044-16-3]  Pexidartinib

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1029044-16-3]

Catalog
HY-16749
Brand
MCE
CAS
1029044-16-3

DESCRIPTION [1029044-16-3]

Overview

MDLMFCD28900745
Molecular Weight417.81
Molecular FormulaC20H15ClF3N5
SMILESFC(C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C43)C=C2)C=N1)(F)F

For research use only. We do not sell to patients.

42 Publications Citing Use of MCE


Summary

Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC 50 s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity [1] .


IC50 & Target

IC50: 10 nM (c-Kit), 20 nM (cFMS), 160 nM (FLT3), 350 nM (KDR), 860 nM (LCK), 880 nM (FLT1), 890 nM (NTRK3) [1]


In Vitro

Pexidartinib (PLX-3397) is a potent, selective and ATP-competitive CSF1R (cFMS) and c-Kit inhibitor, shows 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases, such as FLT3, KDR (VEGFR2), LCK, FLT1 (VEGFR1) and NTRK3 (TRKC), with IC 50 s of 160, 350, 860, 880, and 890 nM, respectively [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

Pexidartinib (PLX3397; 0.25, 1 mg/kg, twice daily for 8 days) inhibits the proliferation of microglia and BrdU-positive cells in neonatal mice [2] .
Pexidartinib (1 mg/kg, twice daily for 8 day) shows no obvious effect on the cleaved caspase-3-positive cells in mice [2] .
Pexidartinib (50 mg/kg; p.o.; every second day for 3 weeks) reduces tissue macrophage levels without affecting glucose homeostasis in mice [4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Neonatal mice [2]
Dosage: 0.25, 1 mg/kg
Administration: I.P. twice daily for 8 days
Result: Decreased the number of microglia and BrdU-positive proliferative cells, but did not change the cleaved caspase-3-positive cells.
Animal Model: 10-week old litter mate C57BL/6 mice (chow and high-fat diet fed mice) [4]
Dosage: 50 mg/kg
Administration: P.o.; every second day for 3 weeks
Result: Substantially reduced macrophage numbers in adipose tissue of both chow and high-fat diet fed mice without affecting total myeloid cell levels.

Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT03158103 Memorial Sloan Kettering Cancer Center|Array BioPharma|Plexxikon
Gastrointestinal Stromal Tumor (GIST)
April 15, 2017 Phase 1
NCT01790503 Daiichi Sankyo, Inc.|Plexxikon
Patients With Newly Diagnosed Glioblastoma
July 18, 2013 Phase 1|Phase 2
NCT04526704 Daiichi Sankyo, Inc.
Tenosynovial Giant Cell Tumor
October 20, 2020 Phase 4

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 239.34 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3934 mL 11.9672 mL 23.9343 mL
5 mM 0.4787 mL 2.3934 mL 4.7869 mL
10 mM 0.2393 mL 1.1967 mL 2.3934 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline

    Solubility: 5 mg/mL (11.97 mM); Suspended solution; Need ultrasonic

  • 2.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.08 mg/mL (4.98 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.98 mM); Clear solution

  • 4.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.98 mM); Clear solution

* All of the co-solvents are available by MCE.


Synonyms

3-Pyridinemethanamine, N-[5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-6-(trifluoromethyl)-
N-[5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-6-(trifluoromethyl)-3-pyridinemethanamine
Pexidartinib
PLX 3397
Turalio